Skip to Main Content

We have a new app!

Take the Access library with you wherever you go—easy access to books, videos, images, podcasts, personalized features, and more.

Download the Access App here: iOS and Android

For instructor materials including Power Points, Answers to Clinical Encounter Questions, please contact

Content Update

September 26, 2023

Spesolimab-sbzo for the management of generalized pustular psoriasis flares: Spesolimab-sbzo was approved by the U.S. Food and Drug Administration on September 1, 2022, for generalized pustular psoriasis flares, based on results of the Effisayil 1 phase II trial. This is the first drug of its kind specifically indicated for treatment of generalized pustular psoriasis (GPP) flares and has a novel mechanism of action; spesolimab-sbzo is an interleukin-36 (IL-36) receptor antagonist that binds to endogenous interleukin to prevent activation of proinflammatory pathways. The American Academy of Dermatology and National Psoriasis Foundation has not yet incorporated spesolimab-sbzo into current clinical practice guidelines for the management and treatment of psoriasis with biologics. Based on clinical trial data, spesolimab-sbzo is considered a treatment option for GPP flares in adults.

Content Update

March 15, 2023

Novel Drugs Approved for Psoriasis in 2022: Tapinarof, deucravacitinib, and spesolimab-sbzo are new medications discussed in this update. Tapinarof is a topical cream for the treatment of plaque psoriasis, and deucravacitinib is an oral tablet indicated for moderate to severe plaque psoriasis. Spesolimab-sbzo is an intravenous infusion approved for generalized pustular psoriasis flares. These medications offer patients additional treatment options to limit the symptoms of psoriasis, which is a complex, immune-mediated disease state.



Upon completion of this chapter, the reader will be able to:

  1. Discuss the etiology of, and risk factors for, psoriasis.

  2. Describe the pathophysiology and clinical presentations of psoriasis.

  3. Delineate treatment goals for patients diagnosed with psoriasis.

  4. Develop an appropriate treatment and care plan for patients diagnosed with psoriasis.

  5. Recommend nonpharmacological and pharmacological treatments for psoriasis.

  6. Recommend appropriate monitoring parameters for patients diagnosed with psoriasis.

  7. Provide education for patients and caregivers as part of the psoriasis care plan.


image Psoriasis is a chronic inflammatory condition that exhibits a cyclical pattern of relapse and remission. There is currently no cure for the disease and treatment is designed to manage signs and symptoms associated with the disease.1 Remission may last years in some, whereas, in others, exacerbations may occur every few months. Patient factors known to exacerbate psoriasis are stress, environmental factors including seasonal changes, and certain medications.2 Depression, alcohol-related problems, cardiovascular diseases, metabolic syndrome, irritable bowel disease (Crohn’s and ulcerative colitis), and skin cancers are select comorbidities associated with the most severe forms of psoriasis.1 Severity of the condition ranges from mild to severely disabling. Thus, management of psoriasis is lifelong, and treatment changes according to the illness severity at the time. Treatment should be individualized to meet patient needs. The disease may cause emotional distress requiring empathy and caring attitude, when making treatment decisions.


Psoriasis is a common chronic inflammatory skin disorder with a ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.